Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Drug-sensitive FGFR2 mutations in endometrial carcinoma.

Dutt, Amit and Salvesen, Helga B and Chen, Tzu-Hsiu and Ramos, Alex H and Onofrio, Robert C and Hatton, Charlie and Nicoletti, Richard and Winckler, Wendy and Grewal, Rupinder and Hanna, Megan and Wyhs, Nicolas and Ziaugra, Liuda and Richter, Daniel J and Trovik, Jone and Engelsen, Ingeborg B and Stefansson, Ingunn M and Fennell, Tim and Cibulskis, Kristian and Zody, Michael C and Akslen, Lars A and Gabriel, Stacey and Wong, Kwok-Kin and Sellers, William and Meyerson, Matthew and Greulich, Heidi (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 105 (25). pp. 8713-8717. ISSN 1091-6490

Abstract

Oncogenic activation of tyrosine kinases is a common mechanism of carcinogenesis and, given the druggable nature of these enzymes, an attractive target for anticancer therapy. Here, we show that somatic mutations of the fibroblast growth factor receptor 2 (FGFR2) tyrosine kinase gene, FGFR2, are present in 12% of endometrial carcinomas, with additional instances found in lung squamous cell carcinoma and cervical carcinoma. These FGFR2 mutations, many of which are identical to mutations associated with congenital craniofacial developmental disorders, are constitutively activated and oncogenic when ectopically expressed in NIH 3T3 cells. Inhibition of FGFR2 kinase activity in endometrial carcinoma cell lines bearing such FGFR2 mutations inhibits transformation and survival, implicating FGFR2 as a novel therapeutic target in endometrial carcinoma.

Item Type: Article
Related URLs:
Additional Information: free full text via PNAS and PubMedCentral
Related URLs:
Date Deposited: 14 Dec 2009 14:06
Last Modified: 31 Jan 2013 01:31
URI: https://oak.novartis.com/id/eprint/72

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.